News

Linda Reuter, CIP, Director of BRANY IRB, discusses the Revised Common Rule that now requires informed consent to begin with a concise and focused presentation of key information that will help the patient better understand the reasons why they might or might not want to participate in the research.

Irina Petrova, Director of Clinical Operations for OCT Clinical Trials, explores why U.S. companies are turning to Russa after having secured approval for 108 trials there in 2018.

Yaky Yanay, CEO of Pluristem, talks with Moe Alsumidaie about his experience and the strategies Pluristem implemented in regenerative medicine clinical trials.

New rules in Denmark to eliminate potential conflict-of-interest issues follow the lead of the European Medicines Agency's repeated attempts to rebut allegations of pro-industry bias.

MyStudies, introduced by the FDA, bridges data streams to real world evidence by facilitating the collection of real-world data directly from patients in conjunction with a variety of data sources.

Peter O'Donnell discusses the European Commission's compendium and how triallists are not only obliged to comply with the current rules, but at the same time to prepare themselves for the future rules.

Click the title above to open the Applied Clinical Trials July/August 2019 issue in an interactive PDF format.

Yaky Yanay, CEO of Pluristem, will discuss his experience and the strategies Pluristem implemented in regenerative medicine clinical trials.